Skip to content

Home Search Authors Pakistan News Saved

SciRah

SciRah does not host or store research papers. Results come live from free, official scholarly APIs, and every paper links back to its original source.

Data sources

OpenAlex
Semantic Scholar
Crossref
CORE
arXiv
PubMed

Privacy policy Terms of service

A. Clamp · SciRah

Researcher profile · Semantic Scholar

A. Clamp

Share profile

A. Clamp — researcher profile on SciRah

h-index: 42
Works: 273
Citations: 6,904

Most-cited papers

Relacorilant and nab-paclitaxel in patients with platinum-resistant ovarian cancer (ROSELLA): an open-label, randomised, controlled, phase 3 trial.
A. Olawaiye, L. Gladieff, David M. O'Malley, Jae-Weon Kim +40 more
2025The Lancet60 citations
Semantic Scholar
Efficacy and Safety of Avutometinib ± Defactinib in Recurrent Low-Grade Serous Ovarian Cancer: Primary Analysis of ENGOT-OV60/GOG-3052/RAMP 201
Susana N. Banerjee, E. Van Nieuwenhuysen, C. Aghajanian, V. D'Hondt +21 more
2025Journal of Clinical Oncology55 citations Open access
Semantic Scholar
The copy number and mutational landscape of recurrent ovarian high-grade serous carcinoma
Philip Smith, T. Bradley, Lena Morrill Gavarró, T. Goranova +32 more
2023Nature Communications55 citations Open access
Semantic Scholar
Clinical and molecular characteristics of ARIEL3 patients who derived exceptional benefit from rucaparib maintenance treatment for high-grade ovarian carcinoma.
D. O'Malley, A. Oza, D. Lorusso, C. Aghajanian +18 more
2022Gynecologic Oncology45 citations Open access
Semantic Scholar
Pembrolizumab in Patients With Advanced Clear Cell Gynecological Cancer
R. Kristeleit, M. Devlin, A. Clamp, C. Gourley +12 more
2025JAMA Oncology42 citations Open access
Semantic Scholar
Weekly dose-dense chemotherapy in first-line epithelial ovarian, fallopian tube, or primary peritoneal cancer treatment (ICON8): overall survival results from an open-label, randomised, controlled, phase 3 trial
A. Clamp, E. James, I. McNeish, A. Dean +28 more
2022The Lancet Oncology39 citations Open access
Semantic Scholar
Initial efficacy and safety results from ENGOT-ov60/GOG-3052/RAMP 201: A phase 2 study of avutometinib (VS-6766) ± defactinib in recurrent low-grade serous ovarian cancer (LGSOC).
Susana Banerjee, K. Ring, E. Van Nieuwenhuysen, M. Fabbro +16 more
2023Journal of Clinical Oncology33 citations Open access
Semantic Scholar
521MO Efficacy of pembrolizumab monotherapy (PM) for advanced clear cell gynaecological cancer (CCGC): Phase II PEACOCC trial
R. Kristeleit, A. Clamp, C. Gourley, R. Roux +8 more
2022Annals of Oncology30 citations Open access
Semantic Scholar
Efficacy and Safety of Weekly Paclitaxel Plus Vistusertib vs Paclitaxel Alone in Patients With Platinum-Resistant Ovarian High-Grade Serous Carcinoma: The OCTOPUS Multicenter, Phase 2, Randomized Clinical Trial.
Susana Banerjee, G. Giannone, A. Clamp, D. Ennis +16 more
2023JAMA Oncology25 citations Open access
Semantic Scholar
Results of a randomised Phase II trial of olaparib, chemotherapy or olaparib and cediranib in patients with platinum-resistant ovarian cancer
S. Nicum, N. McGregor, Rachel Austin, L. Collins +11 more
2024British Journal of Cancer24 citations Open access
Semantic Scholar
O003/#557 Overall survival results from ARIEL3: a phase 3 randomized, double-blind study of rucaparib vs placebo following response to platinum-based chemotherapy for recurrent ovarian carcinoma
R. Coleman, A. Oza, D. Lorusso, C. Aghajanian +15 more
2022Oral Abstracts (Regular and Late-Breaking Submission)24 citations Open access
Semantic Scholar
The impact of olaparib dose reduction and treatment interruption on treatment outcome in the SOLO2/ENGOT-ov21 platinum-sensitive recurrent ovarian cancer.
K. Francis, S. I. Kim, M. Friedlander, V. Gebski +16 more
2022Annals of Oncology24 citations Open access
Semantic Scholar
Overall survival with relacorilant and nab-paclitaxel in patients with platinum-resistant ovarian cancer (ROSELLA): a phase 3 randomised controlled trial.
D. Lorusso, L. Gladieff, D. O'Malley, Jae-Weon Kim +37 more
2026The Lancet22 citations Open access
Semantic Scholar
Efficacy and safety of olaparib according to age in BRCA1/2-mutated patients with recurrent platinum-sensitive ovarian cancer: Analysis of the phase III SOLO2/ENGOT-Ov21 study.
F. Trillsch, S. Mahner, B. Ataseven, R. Asher +17 more
2022Gynecologic Oncology22 citations Open access
Semantic Scholar
2022-RA-249-ESGO Overall survival results from ariel3: a phase 3 randomised, double-blind study of rucaparib vs placebo following response to platinum-based chemotherapy for recurrent ovarian carcinoma
R. Coleman, A. Oza, D. Lorusso, C. Aghajanian +15 more
2022Ovarian cancer21 citations Open access
Semantic Scholar
Homologous recombination deficiency in newly diagnosed FIGO stage III/IV high-grade epithelial ovarian cancer: a multi-national observational study
R. Morgan, A. Clamp, Bethany M. Barnes, K. Timms +22 more
2023International Journal of Gynecological Cancer20 citations Open access
Semantic Scholar
Benefit From Fractionated Dose-Dense Chemotherapy in Patients With Poor Prognostic Ovarian Cancer: ICON-8 Trial
O. Colomban, A. Clamp, A. Cook, I. McNeish +1 more
2023JCO Clinical Cancer Informatics19 citations Open access
Semantic Scholar
Rucaparib for maintenance treatment of platinum-sensitive, recurrent ovarian carcinoma: final results of the phase 3, randomized, placebo-controlled ARIEL3 trial
Jonathan A. Ledermann, A. Oza, D. Lorusso, C. Aghajanian +24 more
2025European Journal of Cancer18 citations Open access
Semantic Scholar
Molecular Results and Potential Biomarkers Identified from the Phase 3 MILO/ENGOT-ov11 Study of Binimetinib versus Physician Choice of Chemotherapy in Recurrent Low-Grade Serous Ovarian Cancer
R. Grisham, I. Vergote, Susana Banerjee, E. Drill +26 more
2023Clinical Cancer Research16 citations Open access
Semantic Scholar
Weekly versus tri-weekly paclitaxel with carboplatin for first-line treatment in women with epithelial ovarian cancer.
N. Ngoi, N. L. Syn, R. M. Goh, Bo-On C. Goh +6 more
2022Cochrane Database of Systematic Reviews15 citations Open access
Semantic Scholar
Phase 2 study of anastrozole in patients with estrogen receptor/progesterone receptor positive recurrent low-grade endometrial stromal sarcomas: The PARAGON trial (ANZGOG 0903).
M. Friedlander, C. Benson, R. O'Connell, N. Reed +16 more
2021Gynecologic Oncology15 citations Open access
Semantic Scholar
Extended panel testing in ovarian cancer reveals BRIP1 as the third most important predisposition gene.
Robert D. Morgan, G. Burghel, N. Flaum, H. Schlecht +14 more
2024Genetics in Medicine14 citations Open access
Semantic Scholar
Maintenance olaparib in patients with platinum-sensitive relapsed ovarian cancer: Outcomes by somatic and germline BRCA and other homologous recombination repair gene mutation status in the ORZORA trial.
S. Pignata, A. Oza, G. Hall, B. Pardo +16 more
2023Gynecologic Oncology14 citations Open access
Semantic Scholar
Rucaparib maintenance treatment for recurrent ovarian carcinoma: the effects of progression-free interval and prior therapies on efficacy and safety in the randomized phase 3 trial ARIEL3
A. Clamp, D. Lorusso, A. Oza, C. Aghajanian +19 more
2021International Journal of Gynecological Cancer13 citations Open access
Semantic Scholar
A first-in-human Phase I dose-escalation trial of the novel therapeutic peptide, ALM201, demonstrates a favourable safety profile in unselected patients with ovarian cancer and other advanced solid tumours
A. El Helali, R. Plummer, G. Jayson, V. Coyle +9 more
2022British Journal of Cancer12 citations Open access
Semantic Scholar
Home Parenteral Nutrition in Patients with Advanced Cancer: Quality Outcomes from a Centralized Model of Care Delivery
M. Kopczynska, A. Teubner, A. Abraham, M. Taylor +8 more
2022Nutrients11 citations Open access
Semantic Scholar
722O Randomised phase II trial of olaparib compared to weekly paclitaxel or olaparib plus cediranib in patients with platinum-resistant ovarian cancer (OCTOVA)
S. Nicum, Jane Holmes, N. McGregor, R. Dunn +12 more
2021Annals of Oncology11 citations Open access
Semantic Scholar
Differential benefit from fractionated dose-dense first-line chemotherapy for epithelial ovarian cancer (EOC) according to KELIM-evaluated tumor primary chemosensitivity: Exploratory analyses of ICON-8 trial.
B. You, A. Clamp, A. Cook, I. McNeish +1 more
202110 citations
Semantic Scholar
Multi-maintenance olaparib therapy in relapsed, germline BRCA1/2-mutant high-grade serous ovarian cancer (MOLTO): a phase II trial.
R. Morgan, A. Clamp, Daniel J White, M. Price +24 more
2023Clinical Cancer Research9 citations
Semantic Scholar
c-MET/VEGFR-2 co-localisation impacts on survival following bevacizumab therapy in epithelial ovarian cancer: an exploratory biomarker study of the phase 3 ICON7 trial
R. Morgan, C. Ferreras, I. Peset, E. Avizienyte +9 more
2022BMC Medicine9 citations Open access
Semantic Scholar
Germline BRCA1/2 status and chemotherapy response score in high-grade serous ovarian cancer
Robert D. Morgan, Xin Wang, Bethany M. Barnes, L. Spurgeon +16 more
2024British Journal of Cancer7 citations Open access
Semantic Scholar
Patients, family members and healthcare professionals' top ten research priorities for adults receiving home parenteral nutrition for malignant or benign disease.
A. Sowerbutts, S. Lal, L. Pironi, Debra J. Jones +8 more
2022Clinical Nutrition ESPEN7 citations Open access
Semantic Scholar
#159 ICON8B: GCIG phase III randomised trial comparing weekly dose-dense chemotherapy + bevacizumab to three-weekly chemotherapy+ bevacizumab in first-line high-risk stage III-IV epithelial ovarian cancer treatment: primary progression-free survival analysis
A. Clamp, I. McNeish, R. Lord, Marcia Hall +16 more
2023Late Breaking Abstracts6 citations Open access
Semantic Scholar
BRCA1/2 in non-mucinous epithelial ovarian cancer: tumour with or without germline testing?
R. Morgan, G. Burghel, N. Flaum, M. Bulman +12 more
2022British Journal of Cancer6 citations Open access
Semantic Scholar
Maintenance olaparib in patients (pts) with platinum-sensitive relapsed ovarian cancer (PSROC) by somatic (s) or germline (g) BRCA and other homologous recombination repair (HRR) gene mutation status: Overall survival (OS) results from the ORZORA study.
S. Pignata, A. Oza, G. Hall, B. Pardo +16 more
2022Journal of Clinical Oncology6 citations
Semantic Scholar
1064O ICON8B: GCIG phase III randomised trial comparing first-line weekly dose-dense chemotherapy + bevacizumab to three-weekly chemotherapy + bevacizumab in high-risk stage III-IV epithelial ovarian cancer (EOC): Final overall survival (OS) analysis
A. Clamp, I. McNeish, D. Radice, R. Lord +15 more
2025Annals of Oncology5 citations Open access
Semantic Scholar
ROSELLA: A phase 3 study of relacorilant in combination with nab-paclitaxel versus nab-paclitaxel monotherapy in patients with platinum-resistant ovarian cancer (GOG-3073, ENGOT-ov72).
A. Olawaiye, L. Gladieff, L. Gilbert, Jae-Weon Kim +16 more
2025Journal of Clinical Oncology5 citations Open access
Semantic Scholar
ORZORA: Maintenance olaparib in patients with platinum-sensitive relapsed ovarian cancer: outcomes by somatic and germline BRCA and other homologous recombination repair gene mutation status
S. Pignata, A. Oza, G. Hall, B. Pardo +15 more
2021Gynecologic Oncology5 citations
Semantic Scholar
LB007/#1548 Efficacy and safety of avutometinib ± defactinib in recurrent low grade serous ovarian cancer: primary analysis of ENGOT-OV60/GOG-3052/RAMP 201
Susana N. Banerjee, C. Aghajanian, E. Van Nieuwenhuysen, A. Santin +16 more
2024Late-Breaking Abstracts4 citations Open access
Semantic Scholar
Factors determining ultra-short-term survival and the commencement of active treatment in high-grade serous ovarian cancer: a case comparison study
A. Hawarden, B. Russell, M. Gee, Fatima Skayali +3 more
2021BMC Cancer4 citations Open access
Semantic Scholar
Maintenance treatment with rucaparib for recurrent ovarian carcinoma in ARIEL3, a randomized phase 3 trial: The effects of best response to last platinum‐based regimen and disease at baseline on efficacy and safety
A. Oaknin, A. Oza, D. Lorusso, C. Aghajanian +20 more
2021Cancer Medicine4 citations Open access
Semantic Scholar
ICON8B: GCIG phase III randomised trial comparing first-line weekly dose-dense chemotherapy + bevacizumab to three-weekly chemotherapy + bevacizumab in high-risk stage III-IV epithelial ovarian cancer: final overall survival (OS) analysis
A. Clamp, I. McNeish, D. Radice, R. Lord +15 more
2026International Journal of Gynecological Cancer3 citations
Semantic Scholar
Impact of KELIM chemosensitivity and interval cytoreduction on survival outcomes from neoadjuvant weekly dose-dense paclitaxel +/- bevacizumab : pooled analysis of ICON8 and ICON8B phase III trials.
B. You, O. Colomban, D. Radice, A. Gentry-Maharaj +6 more
2026International Journal of Gynecological Cancer3 citations
Semantic Scholar
The VALTIVE1 study protocol: a study for the validation of Tie2 as the first tumour vascular response biomarker for VEGF inhibitors
M. Carucci, A. Clamp, Cong Zhou, C. Hurt +19 more
2024BMC Cancer3 citations Open access
Semantic Scholar
Predicting the likelihood of a BRCA1/2 pathogenic variant being somatic by testing only tumour DNA in non-mucinous high-grade epithelial ovarian cancer
R. Morgan, G. Burghel, N. Flaum, M. Bulman +15 more
2022Journal of Clinical Pathology3 citations Open access
Semantic Scholar
2022-RA-1276-ESGO Pembrolizumab monotherapy for advanced clear cell gynaecological cancer: phase II PEACOCC trial
Rowan E. Miller, A. Clamp, C. Gourley, R. Roux +8 more
2022Ovarian cancer3 citations Open access
Semantic Scholar
Long-term efficacy and safety of avutometinib + defactinib in patients with recurrent low-grade serous ovarian cancer: Results from ENGOT-OV60/GOG-3052/RAMP 201
R. Grisham, E. Van Nieuwenhuysen, A. Santin, V. D'Hondt +20 more
2026Gynecologic Oncology2 citations
Semantic Scholar
109RO Continuous relationship between KELIM chemosensitivity and survival benefit from chemotherapy intensification (standard or dose-dense; with/without bevacizumab): ICON8 & 8B
B. You, O. Colomban, D. Radice, A. Gentry-Maharaj +5 more
2026ESMO Open2 citations Open access
Semantic Scholar
SALVOVAR: a pragmatic randomized phase III trial comparing the SALVage weekly dose-dense regimen to the standard 3-weekly regimen in patients with poor prognostic OVARian cancers
Claire Chator, N. Yanaihara, S. Chabaud, G. Parma +13 more
2025Therapeutic Advances in Medical Oncology2 citations Open access
Semantic Scholar
The combination of avutometinib and defactinib in treating recurrent low-grade serous ovarian cancer: a plain language summary of the Phase II clinical trial ENGOT-OV60/GOG-3052/RAMP 201
Susana Banerjee, E. Van Nieuwenhuysen, C. Aghajanian, V. D'Hondt +21 more
2025Future Oncology2 citations Open access
Semantic Scholar

Frequent co-authors

Invite them to SciRah by sharing their profile.

N. Colombo×18
Invite
N. Colombo — researcher profile on SciRah
I. McNeish×14
Invite
I. McNeish — researcher profile on SciRah
A. Oaknin×12
Invite
A. Oaknin — researcher profile on SciRah
A. Oza×10
Invite
A. Oza — researcher profile on SciRah

×10

Invite

J. Ledermann — researcher profile on SciRah

Invite

D. Lorusso — researcher profile on SciRah

R. Glasspool×9

Invite

R. Glasspool — researcher profile on SciRah

Invite

G. Jayson — researcher profile on SciRah

Invite

B. Monk — researcher profile on SciRah

Invite

D. O'Malley — researcher profile on SciRah

C. Aghajanian×7

Invite

C. Aghajanian — researcher profile on SciRah

Susana Banerjee×7

Invite

Susana Banerjee — researcher profile on SciRah